Suppr超能文献

中国杭州不同灭活脊灰疫苗免疫程序的成本效果分析。

Cost-effectiveness of various immunization schedules with inactivated Sabin strain polio vaccine in Hangzhou, China.

机构信息

Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, China.

出版信息

Front Public Health. 2022 Sep 23;10:990042. doi: 10.3389/fpubh.2022.990042. eCollection 2022.

Abstract

BACKGROUND

It is necessary to select suitable inactivated poliovirus vaccine(IPV) and live, attenuated oral poliovirus vaccine (OPV) sequential immunization programs and configure the corresponding health resources. An economic evaluation was conducted on the sequential procedures of Sabin strain-based IPV (sIPV) and bivalent OPV (bOPV) with different doses to verify whether a cost-effectiveness target can be achieved. This study aimed to evaluate the cost-effectiveness of different sIPV immunization schedules, which would provide convincing evidence to further change the poliovirus vaccine (PV) immunization strategies in China.

METHODS

Five strategies were included in this analysis. Based on Strategy 0(S), the incremental cost (IC), incremental effect (IE), and incremental cost-effectiveness ratio (ICER) of the four different strategies (S/S/S/S) were calculated based on the perspective of the society. Seven cost items were included in this study. Results of field investigations and expert consultations were used to calculate these costs.

RESULTS

The ICs of S/S/S/S was Chinese Yuan (CNY) 30.77, 68.58, 103.82, and 219.82 million, respectively. The IE of vaccine-associated paralytic poliomyelitis (IE) cases of S/S/S/S were 0.22, 0.22, 0.22, and 0.11, respectively, while the IE of disability-adjusted life-years (IE) of S/S/S/S were 8.98, 8.98, 8.98, and 4.49, respectively. The ICER of S/S/S/S gradually increased to CNY 13.99, 31.17, 47.19, and 199.83 million/VAPP, respectively. The ICER of S/S/S/S also gradually increased to CNY 0.34, 0.76, 1.16, and 4.90 million/DALY, respectively.

CONCLUSION

ICER and ICER were substantially higher for S (four-sIPV) and S (replacement of self-funded sIPV based on one-sIPV-three-bOPV). Two-sIPV-two-bOPV had a cost-effectiveness advantage, whereas S2/S3/S4 had no cost-effectiveness advantage.

摘要

背景

有必要选择合适的灭活脊灰病毒疫苗(IPV)和减毒口服脊灰病毒疫苗(OPV)序贯免疫程序,并配置相应的卫生资源。本研究对不同剂量的基于沙宾株的 IPV(sIPV)和二价 OPV(bOPV)序贯程序进行了经济性评价,以验证是否可以达到成本效益目标。本研究旨在评估不同 sIPV 免疫方案的成本效益,为进一步改变中国脊灰病毒疫苗(PV)免疫策略提供有力证据。

方法

本研究纳入了 5 种策略。基于策略 0(S),从社会角度计算了四种不同策略(S/S/S/S)的增量成本(IC)、增量效果(IE)和增量成本效益比(ICER)。本研究共纳入 7 项成本。这些成本是通过现场调查和专家咨询来计算的。

结果

S/S/S/S 的 IC 分别为 3077 万元、6858 万元、10382 万元和 21982 万元。S/S/S/S 的疫苗相关麻痹性脊灰病例的 IE 分别为 0.22、0.22、0.22 和 0.11,而 S/S/S/S 的残疾调整生命年的 IE 分别为 8.98、8.98、8.98 和 4.49。S/S/S/S 的 ICER 逐渐增加到 1399 万元/VAPP、3117 万元/VAPP、4719 万元/VAPP 和 19983 万元/VAPP。S/S/S/S 的 ICER 也逐渐增加到 340 万元/DALY、760 万元/DALY、1160 万元/DALY 和 4900 万元/DALY。

结论

S(四价 sIPV)和 S(基于单价 sIPV 的自费 sIPV 替代)的 ICER 和 ICER 明显较高。两价 sIPV-两价 OPV 具有成本效益优势,而 S2/S3/S4 则没有成本效益优势。

相似文献

1
Cost-effectiveness of various immunization schedules with inactivated Sabin strain polio vaccine in Hangzhou, China.
Front Public Health. 2022 Sep 23;10:990042. doi: 10.3389/fpubh.2022.990042. eCollection 2022.
3
Cost-Effectiveness of Three Poliovirus Immunization Schedules in Shanghai, China.
Vaccines (Basel). 2021 Sep 23;9(10):1062. doi: 10.3390/vaccines9101062.
4
Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
Cochrane Database Syst Rev. 2019 Dec 5;12(12):CD011260. doi: 10.1002/14651858.CD011260.pub2.
6
Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010-2014.
Vaccine. 2017 Mar 1;35(9):1281-1286. doi: 10.1016/j.vaccine.2017.01.034. Epub 2017 Feb 1.
8
9
The cost-effectiveness of alternative polio immunization policies in South Africa.
Vaccine. 2006 Jul 17;24(29-30):5670-8. doi: 10.1016/j.vaccine.2006.05.032.
10
[Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV (Ⅰ+Ⅲ) in different dosage forms].
Zhonghua Yu Fang Yi Xue Za Zhi. 2018 Jan 6;52(1):43-49. doi: 10.3760/cma.j.issn.0253-9624.2018.01.009.

引用本文的文献

1
Therapeutic Vaccines for Non-Communicable Diseases: Global Progress and China's Deployment Pathways.
Vaccines (Basel). 2025 Aug 20;13(8):881. doi: 10.3390/vaccines13080881.
3
Should more attention be paid to polio sequela cases in China?
Front Public Health. 2023 Jan 20;10:1076970. doi: 10.3389/fpubh.2022.1076970. eCollection 2022.

本文引用的文献

1
Circulation of Type 2 Vaccine-Derived Poliovirus in China in 2018-2019.
Open Forum Infect Dis. 2021 Oct 17;8(12):ofab535. doi: 10.1093/ofid/ofab535. eCollection 2021 Dec.
2
Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2020-June 2021.
MMWR Morb Mortal Wkly Rep. 2021 Dec 10;70(49):1691-1699. doi: 10.15585/mmwr.mm7049a1.
3
Cost-Effectiveness of Three Poliovirus Immunization Schedules in Shanghai, China.
Vaccines (Basel). 2021 Sep 23;9(10):1062. doi: 10.3390/vaccines9101062.
4
Vaccine-associated paralytic poliomyelitis in the Russian Federation in 1998-2014.
Int J Infect Dis. 2018 Nov;76:64-69. doi: 10.1016/j.ijid.2018.08.017. Epub 2018 Sep 7.
6
Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010-2014.
Vaccine. 2017 Mar 1;35(9):1281-1286. doi: 10.1016/j.vaccine.2017.01.034. Epub 2017 Feb 1.
8
Polio vaccines: WHO position paper, March 2016-recommendations.
Vaccine. 2017 Mar 1;35(9):1197-1199. doi: 10.1016/j.vaccine.2016.11.017. Epub 2016 Nov 25.
9
Phase 3 Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine.
J Infect Dis. 2016 Dec 1;214(11):1728-1734. doi: 10.1093/infdis/jiw433. Epub 2016 Sep 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验